TABLE 1.

Characteristics of HIV-1 glycan and loop lengths in RV217 and RV144 participants^a

Group and parameter	Env PNGS	V1 PNGS	V1 length	V2 PNGS	V2 length	V3 PNGS	V3 length	V4 PNGS	V4 length	V5 PNGS	V5 length
RV217, acute
Min.	22.89	2	21	0	37	0	34	2	19	0	12
Q1	27.99	3.25	28.67	2	40	1	35	4	28	1	13.6
Median	29	4	33.87	2	42	1	35	4	31	1	14
Mean	29.07	4.23	32.96	2.2	42.41	0.98	34.83	4.28	30.48	1.43	14.76
Q3	30.58	5	37	2.5	44	1	35	5	33	2	15
Max.	34.8	8	47	4	51	1	35	6.94	40	3	24
RV217, 6 mo
Min.	24.7	2.38	21	1	37	0.95	34	2	20	0.1	10.4
Q1	28	3.5	31	1.9	40	1	35	3.89	28.05	1	14
Median	29.4	4	34	2	41.78	1	35	4.88	31	1.88	14
Mean	29.12	4.15	32.89	2.17	42.18	1	34.85	4.39	30.81	1.52	14.71
Q3	30.3	4.9	36	2.5	44	1	35	5	33	2	15
Max.	32.56	6.8	44	3.8	51	1	35	6.33	38	2.7	22.07
RV144
Min.	23	2	20.5	0	37	0	33.83	1.17	20	0.8	12
Q1	27.07	4	33	1.88	40	1	35	3	26	1	13.94
Median	28.25	5	35	2	40.5	1	35	4	28	2	15
Mean	28.47	4.68	35.15	2.05	42.12	0.88	35.06	3.68	27.67	1.7	15.2
Q3	29.93	5	37.19	2	44.2	1	35	4	29.81	2	16
Max.	34.8	6.67	47	4.9	61	1	36	6	36.78	3	28

^aSummary measures of the number of PNGS and loop lengths (expressed as the numbers of amino acids) are provided for HIV-1 sequences from RV217 and RV144 participants. Sequences from RV217 participants were sampled in the first month after HIV-1 diagnosis and 6 months later, sequences from RV144 were obtained within the first 6 months of infection. Min., minimum; Max., maximum.